Table 1 DIC with infectious disease: Patients’ characteristics
Background factor | Median (range) or n (%) |
|---|---|
Sex, n (%) | |
 Male | 848 (42.6) |
 Female | 1142 (57.4) |
Age, years | 71 (0–102) |
DIC duration before TM-α treatment, days | 0 (0–51) |
Total dose of TM-α, U/kg | 369.2 (45–609.5) |
Duration of TM-α | 6 (1–27) |
Prior DIC treatment, n (%) | |
 + | 762 (38.3) |
 - | 1228 (61.7) |
Prior heparan sulfate and low molecular weight heparin, n (%) | |
 + | 198 (9.9) |
 - | 1792 (90.1) |
Prior serine protease inhibitors, n (%) | |
 + | 550 (27.6) |
 - | 1440 (72.4) |
Prior AT, n (%) | |
 + | 375 (18.8) |
 - | 1615 (81.2) |
Platelets, 104/μL | 5.2 (0–126) |
PT ratio | 1.32 (0.8–19.06) |
FDP, μg/mL | 29.2 (0.8–3200) |
FBG, mg/dL | 358.7 (0.1885–1481) |
AT, % | 55 (7.5–140) |
JAAM DIC score | 6 (4–8) |
SOFA score | 10 (1–23) |